Bakkt Holdings
BKKT
BIGG DIGITAL ASSETS INC
BBKCF
Ebang International
EBON
BTCS Inc
BTCS
Mawson Infrastructure
MIGI
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.